In the wake of the financial report Intercytex’s stock is down 3.57%. Here’s the link:
Intercytex oughta invest more resources into ICX-TRC, I believe. IF you look at media reports on Intercytex’s IPO in the stock market, almost all of them touted ICX-TRC. Now the media are reporting more on Intercytex’s other products. This is not good news for Intercytex, imho. People turn their ears when they hear “baldness cure”, NOT “diabetic ulcers cure” or “nasolabial folds cure” or “punch excision wound cure”.